Trial Profile
A Phase 1 Dose Escalation, Single Dose Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-278 in HIV-Infected Patients Who Have Exhibited Suboptimal CD4+ T-Cell Gains During Long-Term Antiretroviral Therapy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs SB 728 T (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Sangamo BioSciences
- 14 May 2015 Results presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy, according to a Sangamo Biosciences media release.
- 14 May 2015 Results published in the Media Release.
- 12 Mar 2015 Status changed from active, no longer recruiting to completed As per the ClinicalTrials.gov record